To learn about LOKELMA® (sodium zirconium cyclosilicate), please visit the AstraZeneca booth linked below. You can also visit www.lokelma-hcp.com for more information.
Aurinia is a biopharmaceutical company focused on developing therapies for patient populations impacted by serious diseases with a high unmet medical need. Aurinia recently received FDA approval for their first commercially available drug product. Please visit https://lupkynispro.com to learn more.
Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, IV iron therapy, metastatic melanoma, tenosynovial giant cell tumors and metastatic breast cancer. www.dsi.com
Otsuka America Pharmaceutical, Inc. (OAPI) is an innovative healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S., with a focus on nephrology.
Genzyme is focused in areas of rare diseases, rare blood disorders, multiple sclerosis, oncology, & immunology. Each day we continue to advance new therapies, demonstrating our commitment to making a positive impact on the lives of patients around the world.
Amicus Therapeutics, a patient-dedicated company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, best-in-class medicines.